Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Yamanaka factors, comprising the transcription factors OCT4 (POU5F1), SOX2, KLF4, and c-MYC (OSKM), are the primary drivers of cellular reprogramming from a somatic state to an induced pluripotent stem cell (iPSC) state (Takahashi & Yamanaka, 2006). These factors function by binding to specific genome-wide DNA regulatory elements, including enhancers and promoters, to orchestrate a global reset of the epigenetic and transcriptional landscape (Soufi et al., 2012). OCT4 and SOX2 are essential for maintaining the pluripotency gene regulatory network, while KLF4 and c-MYC act as pioneer factors and metabolic regulators to facilitate chromatin accessibility (Chronis et al., 2017). In a therapeutic context, these factors are utilized to generate patient-specific cells for regenerative medicine and disease modeling. However, their clinical application is challenged by the risk of tumorigenesis, particularly due to the oncogenic potential of c-MYC and KLF4, and the possibility of incomplete epigenetic resetting (Soucek et al., 2008). Small molecules like Valproic acid or CHIR99021 are frequently employed to modulate the activity of these factors and improve the safety and efficiency of the reprogramming process (Huangfu et al., 2008).
Induction of pluripotency through the cooperative binding to genome-wide DNA regulatory elements, leading to the transcriptional activation of pluripotency genes and global epigenetic remodeling of chromatin (Takahashi & Yamanaka, 2006; Soufi et al., 2012).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Yamanaka factors (OCT4, SOX2, KLF4, c-MYC) (OSKM).